{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:10:12Z","timestamp":1762459812448,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.antiviral.2019.104635","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T01:52:51Z","timestamp":1571277171000},"page":"104635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference."],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"Andrea","family":"Giacomelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Franzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Pecorari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Monno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Vicenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Paolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104635_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104635_bib2","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","author":"Andreatta","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.antiviral.2019.104635_bib3","first-page":"443","article-title":"An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project","volume":"38","author":"Andreoni","year":"2015","journal-title":"New Microbiol."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104635_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hiv.12688","volume":"20","author":"Baldin","year":"2019","journal-title":"HIV Med."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104635_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijantimicag.2019.03.016","article-title":"Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients","volume":"54","author":"Chen","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.antiviral.2019.104635_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravirbased regimen versus continuation of a lopinavir-ritonavirbased regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.antiviral.2019.104635_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/cid\/ciy505","volume":"68","author":"Gatell","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104635_bib8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2147\/DDDT.S204415","article-title":"Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects","volume":"13","author":"Giacomelli","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.antiviral.2019.104635_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(19)30035-0","article-title":"Dolutegravir for second-line antiretroviral therapy","volume":"19","author":"Hamers","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2019.104635_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med."},{"issue":"7","key":"10.1016\/j.antiviral.2019.104635_bib12","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(18)30710-2","article-title":"Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens","volume":"19","author":"Inzaule","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2019.104635_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104635_bib14","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIVinfected patients: the SPIRAL study","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.antiviral.2019.104635_bib15","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/QAD.0000000000001495","article-title":"Dolutegravir and weight gain: an unexpected bothering side effect?","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.antiviral.2019.104635_bib16","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2019.104635_bib17","article-title":"Impact of the M184V\/I Mutation on the Efficacy of Abacavir\/Lamivudine\/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients","author":"Olearo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104635_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"11","key":"10.1016\/j.antiviral.2019.104635_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-na\u00efve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl. 5","key":"10.1016\/j.antiviral.2019.104635_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12440","article-title":"Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens","volume":"17","author":"Raffi","year":"2016","journal-title":"HIV Med."},{"issue":"5","key":"10.1016\/j.antiviral.2019.104635_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations","volume":"51","author":"S\u00f6rstedt","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.antiviral.2019.104635_bib22","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.antiviral.2019.104635_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3851\/IMP3192","article-title":"Correction: dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir. Ther."},{"issue":"6","key":"10.1016\/j.antiviral.2019.104635_bib24","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:32Z","timestamp":1759062572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219305261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":23,"alternative-id":["S0166354219305261"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104635","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104635"}}